RGBOQ   $0.0008  -11.11% Market Closed

ReGen Biologics Inc
Last Events:

2021-09-23 Signal in EMA50 changed from bearish reversal to n/a. 2021-05-20 the price crossed down the moving average line and demonstrates a strong downside trend.

2021-09-22 Signal in EMA50 changed from n/a to bearish reversal. 2021-05-20 the price crossed down the moving average line and demonstrates a strong downside trend.

2021-09-21 Signal in EMA50 changed from bearish reversal to n/a. 2021-05-20 the price crossed down the moving average line and demonstrates a strong downside trend.

2021-09-16 Signal in Stochastic changed from bearish reversal to bearish. The stochastic indicator is in the lower part of the neutral territory and it falls. These factors indicate that negative dynamics persists. Last signal: down-crossing the middle level.

2021-08-31 Signal in Stochastic changed from bullish to bearish reversal. The stochastic indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: main and signal line crossing.

2021-08-31 Signal in MACD changed from bullish reversal to bearish recovery. Oscillator MACD is in the negative territory it crossed the signal line from the top and falls. These factors mean that the market confirms the tendency to fall. Last signal: main and signal line crossing.

2021-08-31 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2021-08-29 Trend pattern changed from расходящийся клин с наклоном вверх to канал.


Current temperature: 0.00
ST: 0, Cor:

Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy -
rsi ActivelyBuy - -
macd ActivelyBuy ActivelyBuy -
stoch Buy Buy -
ma20 - - -
ma50 - - -
ma100 - - -
ISIN US75884M3025
ReGen Biologics Inc. designs, develops, manufactures, and markets medical devices for the repair and generation of soft tissue in humans, primarily for orthopedic applications. The company's proprietary collagen matrix technology includes applications in orthopedics, general surgery, spine, cardiovascular, and drug delivery. Its products include Menaflex collagen meniscus implant device, for use in surgical procedures for the reinforcement and repair of soft tissue injuries of the medial meniscus; and SharpShooter Tissue Repair System, an instrument that allows surgeons to place needles in hard-to-reach locations of the meniscus. The company sells its products in the United States, the European Union, the Republic of South Africa, Canada, Australia, Chile, and Japan. ReGen Biologics Inc. was formerly known as Aros Corp and changed its name to ReGen Biologics Inc. in November, 2002. ReGen Biologics Inc. was founded in 1987 and is headquartered in Hackensack, New Jersey. On April 8, 2011, ReGen Biologics Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on October 14, 2011.